Adverse pregnancy outcomes with isoniazid preventive therapy in HIV

Post Date: 
2018-03-09
Source: 
Infectious Disease Advisor

. . . The safety of IPT in pregnant women with HIV is unknown, especially with regard to its combination with highly active antiretroviral therapy (ART). Amita Gupta, MD, deputy director of the Johns Hopkins University Center for Clinical Global Health Education at the Johns Hopkins University School of Medicine, and colleagues hypothesized that IPT can be safely initiated during pregnancy in this population. In a phase 4 randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT01494038), 956 HIV-positive women on ART from tuberculosis-endemic areas in Africa, Asia, and Haiti were randomly assigned 1:1 to receive immediate/antepartum IPT (n=477) or deferred/postpartum IPT (n=479) . . .